Compare OBIO & ALTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBIO | ALTI |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | United States | United States |
| Employees | N/A | 490 |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.4M | 334.9M |
| IPO Year | 2020 | 2021 |
| Metric | OBIO | ALTI |
|---|---|---|
| Price | $5.61 | $2.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $12.43 | N/A |
| AVG Volume (30 Days) | ★ 295.8K | 120.7K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.13 | ★ 41.11 |
| EPS | N/A | ★ N/A |
| Revenue | $33,482,000.00 | ★ $254,956,000.00 |
| Revenue This Year | N/A | $17.39 |
| Revenue Next Year | $33.03 | $9.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1169.22 | 23.21 |
| 52 Week Low | $3.46 | $2.26 |
| 52 Week High | $6.50 | $5.45 |
| Indicator | OBIO | ALTI |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 41.05 |
| Support Level | $5.54 | $2.26 |
| Resistance Level | $5.78 | $3.97 |
| Average True Range (ATR) | 0.34 | 0.17 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 33.75 | 45.45 |
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.